ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
21.12.2019 11:46:00 EET | Business Wire | Press release
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its application for cabotegravir and rilpivirine long-acting regimen for treatment of HIV-1 infection in virologically suppressed adults.
The reasons given in the CRL relate to Chemistry Manufacturing and Controls (CMC). There have been no reported safety issues related to CMC and there is no change to the safety profile of the products used in clinical trials to date. ViiV Healthcare will work closely with the FDA to determine the appropriate next steps for this New Drug Application.
Cabotegravir is an integrase strand transfer inhibitor developed by ViiV Healthcare and rilpivirine is a non-nucleoside reverse transcriptase inhibitor developed by Janssen Sciences Ireland UC. The cabotegravir and rilpivirine long-acting regimen is an investigational product and not approved anywhere in the world.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.
For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com.
About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2018.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person responsible for arranging the release of this announcement on behalf of GSK is V.A. Whyte, Company Secretary.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191221005008/en/
Contact information
ViiV Healthcare Media enquiries:
Audrey Abernathy, +1 919 605 4521
Stephen Rea, +44 (0) 78 8126 9009
GSK Global Media enquiries:
Simon Steel, +44 (0) 20 8047 5502
Kathleen Quinn, +1 202 603 5003
Analyst/Investor enquiries:
Sarah Elton-Farr, +44 (0) 20 8047 5194
Danielle Smith, +44 (0) 20 8047 0932
James Dodwell, +44 (0) 20 8047 2406
Jeff McLaughlin, +1 215 751 7002
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Announces Chris Perkin Appointed Executive Chairman; Marie-Hélène Raigneau Appointed Chief Executive Officer11.2.2026 22:14:00 EET | Press release
Altasciences announced today that Chris Perkin has been appointed Executive Chairman of the company’s Board of Directors, effective Tuesday, February 24, 2026. Following a leadership transition that has been underway for the past 12 months, Marie-Hélène Raigneau, President of the company since April 2025, has been appointed Chief Executive Officer, also effective Tuesday, February 24, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260211203073/en/ From left to right: Chris Perkin, Executive Chairman of the Board (Altasciences), and Marie-Hélène Raigneau, Chief Executive Officer (Altasciences). “Having worked alongside Marie-Hélène for over two decades, I am fully confident in her readiness to guide Altasciences forward with clarity and purpose,” said Chris. “I am happy to be stepping aside after 50 years in drug development, knowing that Altasciences is well-positioned for the future.” Chris joined Altasciences as CEO
Sodali & Co Hires BlackRock Investment Stewardship AI and Data Lead11.2.2026 21:20:00 EET | Press release
Sodali & Co, the leading global capital markets-centric stakeholder advisory firm, is pleased to announce that Brett Miller has joined the firm as Global Head of Data Analytics based in New York. Miller joins from BlackRock where he served as Head of Data Analytics for its Investment Stewardship team. In his new role, Miller will lead Sodali’s global AI and data analytics strategy and embed data-driven insight across the firm’s integrated Shareholder Services, Sustainability, and Strategic Communications offering to help support clients navigate the increasingly complex and interconnected governance, investor, and stakeholder landscape. Miller joins Sodali & Co. at a time when investors are rapidly leveraging data and AI to drive investment and voting decisions. He will lead the buildout of an advanced analytics and technology platform to give clients actionable insight into how their narrative is driving capital flow and voting behavior. These capabilities will empower clients to make
Egon Zehnder Opens Philadelphia Office to Support Leaders in the Region’s Fast-Growing Economy11.2.2026 19:44:00 EET | Press release
Egon Zehnder, the world’s premier leadership advisory and executive search firm, today announced the opening of its Philadelphia office, marking the firm’s 70th office globally and further expanding its footprint in the United States. The new location strengthens Egon Zehnder’s long-standing commitment to serving clients across the Mid-Atlantic region with an integrated, advisory-led approach to leadership. Located in the FMC Tower, the Philadelphia office will deliver Egon Zehnder’s full suite of leadership advisory services and executive search to the region, including CEO succession, board effectiveness, executive search, leadership assessments, executive development, culture and organizational transformation and team effectiveness. The office will be staffed by consultants who live and work in the community, pairing global insights with local business operating realities to advise clients. Ari Roitman will lead the Philadelphia office, bringing extensive experience across leadershi
Andersen Consulting Expands Platform in North America with Addition of Kezber11.2.2026 16:30:00 EET | Press release
Andersen Consulting strengthens its business transformation and cybersecurity offerings with the addition of Canadian-based collaborating firm Kezber. Founded in 1996, Kezber specializes in providing a full suite of IT solutions including managed IT services, infrastructure support, cybersecurity, cloud services, custom software development, business intelligence and AI services, and business process automation. The firm works with organizations to enhance productivity, modernize their technology environments, and leverage data-driven solutions to achieve strategic objectives. "Our collaboration with Andersen Consulting allows us to bring our full suite of software and IT services into a broader consulting framework," said Alan Kezber, CEO of Kezber. "By integrating our technical expertise with Andersen Consulting’s comprehensive consulting capabilities, we can offer clients solutions that drive operational improvements and support sustainable growth." "Kezber’s deep technology experti
Uniswap Labs and Securitize Collaborate to Unlock Liquidity Options for BlackRock’s BUIDL11.2.2026 16:00:00 EET | Press release
Uniswap Labs, the leader in decentralized finance, and Securitize, the leader in tokenizing real-world assets (RWAs), today announced a strategic integration to make BlackRock USD Institutional Digital Liquidity Fund (BUIDL) shares available to trade via UniswapX technology. This integration will enable onchain trading of BUIDL, both unlocking new liquidity options for BUIDL holders, and marking a significant step in bridging the gap between traditional finance and DeFi. “Our mission at Labs is simple: make exchanging value cheaper, faster and more accessible,” said Hayden Adams, Uniswap Labs Founder and CEO. “Enabling BUIDL on UniswapX with BlackRock and Securitize supercharges our mission by creating efficient markets, better liquidity, and faster settlement. I’m excited to see what we build together.” Securitize Markets will facilitate trading for any BUIDL investor who elects to participate through UniswapX’s RFQ framework. The automated system enables participants to identify the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom